Selected research
Industry Growth & Trends
Global Psoriasis Biosimilar Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Psoriasis Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Psoriasis Biosimilar market include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Psoriasis Biosimilar market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Psoriasis Biosimilar market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Psoriasis Biosimilar market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Psoriasis Biosimilar.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Psoriasis Biosimilar market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Psoriasis Biosimilar Market by Company
Amgen Inc
Celltrion
Coherus BioSciences
Fresenius Kabi
GenScript
Gyros Protein Technologies AB
Hoffmann-La Roche Ltd
Novartis International AG
Reddy's Laboratories
Samsung Bioepis
Samsung Bioepis Co., Ltd.
Viatris
Pfizer Inc.
Merck KGaA
Sandoz
Psoriasis Biosimilar Segment by Type
TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Other Biosimilars
Psoriasis Biosimilar Segment by Application
Plaque Psoriasis
Psoriatic Arthritis
Other
Psoriasis Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Psoriasis Biosimilar companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- Other Biosimilars
Applications
- Plaque Psoriasis
- Psoriatic Arthritis
- Other
Companies covered
- Amgen Inc
- Celltrion
- Coherus BioSciences
- Fresenius Kabi
- GenScript
- Gyros Protein Technologies AB
- Hoffmann-La Roche Ltd
- Novartis International AG
- Reddy's Laboratories
- Samsung Bioepis
- Samsung Bioepis Co., Ltd.
- Viatris
- Pfizer Inc.
- Merck KGaA
- Sandoz
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Psoriasis Biosimilar Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Psoriasis Biosimilar Market Size by Region (2021-2032)
- 1.4.1 Global Psoriasis Biosimilar Market Size by Region (2021-2026)
- 1.4.2 Global Psoriasis Biosimilar Market Size by Region (2027-2032)
- 1.5 Key Regions Psoriasis Biosimilar Market Size (2021-2032)
- 1.5.1 North America Psoriasis Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Psoriasis Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Psoriasis Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.4 South America Psoriasis Biosimilar Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Psoriasis Biosimilar Market Size Growth Rate (2021-2032)
2 Psoriasis Biosimilar Market by Type
- 2.1 Type Introduction
- 2.1.1 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- 2.1.2 Other Biosimilars
- 2.2 Global Psoriasis Biosimilar Market Size by Type
- 2.2.1 Global Psoriasis Biosimilar Market Size Overview by Type (2021-2032)
- 2.2.2 Global Psoriasis Biosimilar Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Psoriasis Biosimilar Market Size Forecasted by Type (2027-2032)
- 2.3 Global Psoriasis Biosimilar Market Size by Regions
- 2.3.1 North America Psoriasis Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Psoriasis Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Psoriasis Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Psoriasis Biosimilar Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Psoriasis Biosimilar Market Size Breakdown by Type (2021-2026)
3 Psoriasis Biosimilar Market by Application
- 3.1 Type Introduction
- 3.1.1 Plaque Psoriasis
- 3.1.2 Psoriatic Arthritis
- 3.1.3 Other
- 3.2 Global Psoriasis Biosimilar Market Size by Application
- 3.2.1 Global Psoriasis Biosimilar Market Size Overview by Application (2021-2032)
- 3.2.2 Global Psoriasis Biosimilar Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Psoriasis Biosimilar Market Size Forecasted by Application (2027-2032)
- 3.3 Global Psoriasis Biosimilar Market Size by Regions
- 3.3.1 North America Psoriasis Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Psoriasis Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Psoriasis Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Psoriasis Biosimilar Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Psoriasis Biosimilar Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Psoriasis Biosimilar Industry Trends
- 4.2 Psoriasis Biosimilar Industry Drivers
- 4.3 Psoriasis Biosimilar Industry Opportunities and Challenges
- 4.4 Psoriasis Biosimilar Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Psoriasis Biosimilar Revenue (2021-2026)
- 5.2 Global Psoriasis Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Psoriasis Biosimilar Key Company Headquarters & Area Served
- 5.4 Global Psoriasis Biosimilar Company, Product Type & Application
- 5.5 Global Psoriasis Biosimilar Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Psoriasis Biosimilar Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Psoriasis Biosimilar Players Market Share by Revenue in 2025
- 5.6.3 2025 Psoriasis Biosimilar Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Amgen Inc
- 6.1.1 Amgen Inc Company Information
- 6.1.2 Amgen Inc Business Overview
- 6.1.3 Amgen Inc Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
- 6.1.5 Amgen Inc Recent Developments
- 6.2 Celltrion
- 6.2.1 Celltrion Company Information
- 6.2.2 Celltrion Business Overview
- 6.2.3 Celltrion Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
- 6.2.5 Celltrion Recent Developments
- 6.3 Coherus BioSciences
- 6.3.1 Coherus BioSciences Company Information
- 6.3.2 Coherus BioSciences Business Overview
- 6.3.3 Coherus BioSciences Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
- 6.3.5 Coherus BioSciences Recent Developments
- 6.4 Fresenius Kabi
- 6.4.1 Fresenius Kabi Company Information
- 6.4.2 Fresenius Kabi Business Overview
- 6.4.3 Fresenius Kabi Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
- 6.4.5 Fresenius Kabi Recent Developments
- 6.5 GenScript
- 6.5.1 GenScript Company Information
- 6.5.2 GenScript Business Overview
- 6.5.3 GenScript Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 GenScript Psoriasis Biosimilar Product Portfolio
- 6.5.5 GenScript Recent Developments
- 6.6 Gyros Protein Technologies AB
- 6.6.1 Gyros Protein Technologies AB Company Information
- 6.6.2 Gyros Protein Technologies AB Business Overview
- 6.6.3 Gyros Protein Technologies AB Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
- 6.6.5 Gyros Protein Technologies AB Recent Developments
- 6.7 Hoffmann-La Roche Ltd
- 6.7.1 Hoffmann-La Roche Ltd Company Information
- 6.7.2 Hoffmann-La Roche Ltd Business Overview
- 6.7.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
- 6.7.5 Hoffmann-La Roche Ltd Recent Developments
- 6.8 Novartis International AG
- 6.8.1 Novartis International AG Company Information
- 6.8.2 Novartis International AG Business Overview
- 6.8.3 Novartis International AG Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
- 6.8.5 Novartis International AG Recent Developments
- 6.9 Reddy's Laboratories
- 6.9.1 Reddy's Laboratories Company Information
- 6.9.2 Reddy's Laboratories Business Overview
- 6.9.3 Reddy's Laboratories Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
- 6.9.5 Reddy's Laboratories Recent Developments
- 6.10 Samsung Bioepis
- 6.10.1 Samsung Bioepis Company Information
- 6.10.2 Samsung Bioepis Business Overview
- 6.10.3 Samsung Bioepis Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
- 6.10.5 Samsung Bioepis Recent Developments
- 6.11 Samsung Bioepis Co., Ltd.
- 6.11.1 Samsung Bioepis Co., Ltd. Company Information
- 6.11.2 Samsung Bioepis Co., Ltd. Business Overview
- 6.11.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
- 6.11.5 Samsung Bioepis Co., Ltd. Recent Developments
- 6.12 Viatris
- 6.12.1 Viatris Company Information
- 6.12.2 Viatris Business Overview
- 6.12.3 Viatris Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Viatris Psoriasis Biosimilar Product Portfolio
- 6.12.5 Viatris Recent Developments
- 6.13 Pfizer Inc.
- 6.13.1 Pfizer Inc. Company Information
- 6.13.2 Pfizer Inc. Business Overview
- 6.13.3 Pfizer Inc. Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
- 6.13.5 Pfizer Inc. Recent Developments
- 6.14 Merck KGaA
- 6.14.1 Merck KGaA Company Information
- 6.14.2 Merck KGaA Business Overview
- 6.14.3 Merck KGaA Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
- 6.14.5 Merck KGaA Recent Developments
- 6.15 Sandoz
- 6.15.1 Sandoz Company Information
- 6.15.2 Sandoz Business Overview
- 6.15.3 Sandoz Psoriasis Biosimilar Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
- 6.15.5 Sandoz Recent Developments
7 North America
- 7.1 North America Psoriasis Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Psoriasis Biosimilar Market Size by Country (2021-2026)
- 7.3 North America Psoriasis Biosimilar Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Psoriasis Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Psoriasis Biosimilar Market Size by Country (2021-2026)
- 8.3 Europe Psoriasis Biosimilar Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Psoriasis Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Psoriasis Biosimilar Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Psoriasis Biosimilar Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Psoriasis Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Psoriasis Biosimilar Market Size by Country (2021-2026)
- 10.3 South America Psoriasis Biosimilar Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Psoriasis Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Psoriasis Biosimilar Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Psoriasis Biosimilar Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst